ArticleMicrobiologyOpen2024
Bacillus xiamenensis Inhibits the Growth of Moraxella osloensis by Producing Indole-3-Carboxaldehyde.
Article in MicrobiologyOpen, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Moraxella osloensis, a gram-negative rod-shaped bacterium found on human skin, produces 4-methyl-3-hexenoic acid, contributing to clothing and body malodor. M. osloensis is resistant to UV light, drying, and antimicrobials, making its eradication challenging. As the skin is low in nutrients, commensal bacteria compete for resources and use diverse strategies to inhibit their competitors. Therefore, skin-derived bacteria that exhibited growth-inhibitory activity against M. osloensis were searched. Screening skin-derived bacteria using a coculture halo assay revealed that Bacillus xiamenensis formed an inhibition zone with M. osloensis. Coculture plates were extracted with ethyl acetate and fractionated using a silica gel column and preparative thin-layer chromatography to isolate the active compound from the B. xiamenensis metabolites. Nuclear magnetic resonance spectroscopy identified the active compound as indole-3-carboxaldehyde, which has low toxicity in humans. At soluble concentrations, indole-3-carboxaldehyde does not inhibit the growth of other bacteria, such as Staphylococcus aureus, Escherichia coli, and Bacillus subtilis, suggesting M. osloensis is highly sensitive to indole-3-carboxaldehyde. These findings highlight B. xiamenensis as a promising candidate for the development of a skin probiotic to promote skin health and combat malodor-causing bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.